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Abstract
Maternal consumption of a Western diet (WD) has been linked to alterations in fetoplacental
metabolic programming and risk for the exposed fetus to develop obesity, cardiovascular
disease, and type II diabetes mellitus. It may also cause oxidative damage to the placental
mitochondria. This thesis investigated the metabolic effects of a WD on placentae using a
guinea pig model of pregnancy and hyperpolarized 13C MRI for metabolic quantification. It
was hypothesized that placental glycolytic metabolism would increase, and placental
oxidative metabolism would decrease in WD-fed sows. Control diet- and WD-fed, pregnant
sows underwent metabolic MRI at 33 days gestation and were investigated by quantifying
the placental lactate-, alanine-, and bicarbonate-to-pyruvate ratios. A statistically significant
relationship was detected between placental appearance and metabolism that could be useful
as a biomarker of fetoplacental health. These results reinforce the importance of placental
metabolic research to determine the relationship between WD consumption and placental
metabolism.
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Summary for Lay Audience
This thesis investigated the effects of eating a high-fat, high-sugar diet during pregnancy.
This type of diet is known as the Western diet (WD). The placenta is a temporary but critical
organ of pregnancy that can be affected by a WD. The placenta supports the baby’s growth
and development and provides nutrients. Eating a WD has the potential to impact our shortand long-term health negatively. Eating a WD can alter epigenetic mechanisms. These
mechanisms influence how our bodies respond to and process the foods we eat. Changes to
these mechanisms predispose a person to develop adverse health conditions. Eating a WD
exposes the placenta to a toxic environment. This toxic environment may damage cellular
structures and mechanisms involved in metabolism. It alters the processes our bodies use to
derive energy from food. This study sought to detect these changes early in pregnancy. Early
detection of these changes could be useful as a diagnostic tool. A diagnostic tool would be
useful for understanding and detecting babies in metabolic distress. It was expected that
eating a WD would result in less efficient methods of energy production. This study
investigated metabolic changes in the placenta. A guinea pig model of pregnancy was used
because guinea pigs have a similar placental structure and function to the human placenta.
Guinea pigs were fed either a WD or a control diet. At mid-pregnancy, guinea pigs
underwent specialized MRI techniques to measure metabolism and assess the physical
characteristics of the placenta. No significant relationship was detected between diet and
metabolism. However, a significant relationship was detected between placental
characteristics and metabolism, and this relationship may be a useful indicator of a baby’s
health. Future work should include the collection of extra mid-pregnancy data.
Understanding babies in metabolic distress is critical to our short- and long-term health.
Future studies need to clarify the relationship between diet and a baby's health.
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Chapter 1

1

Introduction

This thesis introduction begins by describing the normal progression of pregnancy, as
well as complications that may be encountered during pregnancy. Next, in utero
environmental exposures and obesity and its effects during pregnancy are examined.
Third, this thesis provides background information on the Western diet, metabolic
programming, and placental development, role, and metabolism. Additionally, current
monitoring methods of fetoplacental health and hyperpolarized magnetic resonance
imaging are described. Last, this introduction examines analysis methods and animal
models.

1.1 Pregnancy
Pregnancy in humans refers to the period during which a fetus develops within a female’s
uterus. A typical gestational period is approximately 40 weeks and is measured from the
first day of the last menstrual period (LMP) to delivery. The gestational age (GA) of a
fetus refers to the current duration of pregnancy. It is counted from the first day of the last
menstrual period. GA is usually expressed in weeks and days, and pregnancy is
commonly divided into three trimesters. The first trimester lasts from zero days LMP to
the end of the 13thweek of pregnancy. This trimester encompasses events such as rapid
cell divisions, placentation, and embryonic organogenesis. The first trimester of
pregnancy is a critical period of development, during which time the embryo/fetus is
particularly sensitive to disruptions in its environment and development. The second
trimester lasts from 14 weeks to the end of the 27th week [1]. During this period, we see
continued development of the fetal form and function [2] and a fully developed and
functioning placenta [1]. The third trimester lasts from the 28th week of pregnancy until
delivery. By this time, the fetus is mostly developed and gains weight rapidly [2],
attributable primarily to the increasing development of subcutaneous adipose tissue [3].
The placenta, while still supporting the fetus, matures and follows a normal path of
decline approaching the delivery of the fetus, which marks the end of pregnancy [1].
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1.1.1

Placenta

The placenta is a fetal organ that exists only during pregnancy and acts as an interface
between the maternal and fetal environment to support fetal growth and development.
Anatomically, the placenta has a “maternal side,” known as the basal plate and a “fetal
side,” known as the chorionic plate. The basal plate is formed by the decidua basalis,
which is the term given to the layer of decidua that lies deep to the conceptus. The
decidua is the term given to the functional layer of endometrium in a gravid uterus [1].
The chorionic plate is composed of the amniochorionic membrane and fetal vessels [4].
The human placenta is known to be hemochorial in structure, meaning that there is a
single layer of chorionic cells (syncytiotrophoblasts) separating maternal and fetal
circulation of red blood cells [5].

Typically, the placenta is a flattened, circular, metabolically active, highly vascularized
and low-resistance organ that weighs approximately 600 grams at term and is 2-4cm
thick depending on gestational age. It can attach to the uterine wall anywhere within the
uterine cavity, with the maternal side being comprised of nearly 20 functional lobes
composed of maternal sinusoids and chorionic villous structures. Generally, the placenta
has a homogeneous tissue texture and smooth borders with central insertion of the
umbilical cord - the vascular connection between the fetus and placenta.
The retroplacental complex is a 20cm-thick, vascularized zone just deep to (or
underneath) the basal plate of the placenta and is composed of decidua basalis, uterine
myometrium, and maternal veins, which drain the placenta [1]. The gross placental
structure and umbilical cord can be seen in Figure 1.
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umbilical
cord

chorionic
plate

basal plate

Figure 1: The placenta (figure adapted [6, 7]). The umbilical cord is seen inserting
into the placenta. The chorionic plate is seen on the fetal side, and the basal plate is
seen on the maternal side of the placenta.

1.1.1.1

Placental Development

The placenta is composed of parenchyma, chorion, amnion, and the umbilical cord. The
trophoblast is formed from the trophectoderm. Contact between the endometrium and the
trophoblast, during implantation of the blastocyst, initiates the development of the
syncytiotrophoblast and the cytotrophoblast. The cytotrophoblast secretes enzymes that
erode the endometrial cells and allows for invasion of the endometrial wall by
syncytiotrophoblast cells [4].

The placenta is formed by the chorion, which is composed of syncytiotrophoblast,
cytotrophoblast, and extraembryonic mesoderm. The syncytiotrophoblasts and
cytotrophoblasts are specialized placental cells that line the chorionic villi. The
cytotrophoblast pushes into the syncytiotrophoblast, forming finger-like projections
called the primary chorionic villi. The secondary chorionic villi are formed when the
extraembryonic mesoderm divides into splanchnic and somatic mesoderm. The
completed formation of blood cells and vessels from mesenchyme marks the presence of
tertiary chorionic villi. A vascular network then develops from the villi connecting to the
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embryonic heart as the villi continue to grow and branch into the chorion, bathed in
maternal blood in the intervillous spaces from remodelled maternal uterine spiral arteries
in each of the functional lobes of the placenta. As placental development continues, the
amnion and chorion fuse. Together with the fetal vessels, this forms the chorionic plate
of the placenta. By the third month of pregnancy, the placenta is fully developed and is
functioning to support the developing fetus [4].

1.1.1.2

Role of the Placenta

The placenta is considered to be an immune and endocrine organ that functions to support
fetal growth and development by acting as an interface between maternal and fetal
environments. The exchange of maternal and fetal substances occurs across the chorionic
membrane of the villi and the intervillous spaces containing maternal blood. Oxygen and
carbon dioxide, hormones, maternal antibodies, electrolytes, fetal waste, and nutrition for
the fetus in the form of amino acids, water, vitamins, free fatty acids, and glucose are
exchanged across the membrane [4]. Figure 2 demonstrates placentation.

Figure 2: Placentation [8, 9]. The chorionic villi are seen deep to the chorion,
surrounded by the intervillous spaces and bathed in maternal blood for the
exchange of nutrients, gases, and waste.

1.1.1.3

Placental Metabolism

Metabolically, the placenta serves to produce glycogen (from maternal glucose) and
cholesterol (from maternal fatty acids). The cholesterol produced is used to generate
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hormones like estrogen, progesterone, and glucocorticoids that help to sustain the
pregnancy and influence fetal development [4]. The placenta also synthesizes peptide
hormones such as vascular endothelial growth factor (VEGF) and placental growth factor
(PIGF), which have a role in placental development and maternal spiral artery
remodelling [10]. Glycogen produced in the placenta is stored for use as energy for the
fetus [4].
While the placenta provides energy via glycogen storage to the fetus, the placenta itself
requires energy from glucose to function. The fetal environment is known to be naturally
hypoxic [11], and levels of oxygen in the placenta during the first trimester are also
naturally low [12]. In this low-oxygen state, energy for the placenta is derived from the
production of lactate through aerobic glycolysis [13].
The presence of an adverse maternal metabolic environment has the potential to alter the
normal metabolic processes and efficiency of the placenta. Some studies have shown that
a high fat, high sugar maternal environment leads to abnormal accumulation of lipids in
the placenta and also suggest that exposure of the placenta to a lipotoxic environment
may lead to oxidative damage to placental mitochondria, the cellular organelles
responsible for placental metabolism and energy production [14, 15].

1.1.1.4

The Uterus

The uterus is a muscular organ that forms part of the female reproductive system. The
uterus is where implantation and growth of a conceptus occurs and plays a significant
role in the labour and delivery of a fetus by producing strong muscle contractions that
ultimately expel the fetus from the uterus during the birthing process. There are four
segments to the uterus - the fundus, the corpus, the isthmus, and the cervix. The uterus
contains an internal cavity, which is lined with endometrium - a mucosa, which is the
innermost of three uterine layers of tissue. The outermost layer is the serosa, which is
thin. The middle layer is the thick, muscular layer called the myometrium [1].
The endometrium is a specialized mucosal tissue that responds to changes in hormone
levels throughout the menstrual cycle by altering its thickness and composition to
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accommodate and support the implantation of a fragile conceptus. The endometrium has
two layers: a superficial functional layer and a deep basal layer. It is the functional layer
of the endometrium that is termed the decidua in the gravid uterus. The decidua is further
subdivided based on its anatomical relationship to the implanted conceptus. The decidua
basalis is deep to the conceptus, and the decidua capsularis overlies the conceptus.
Finally, the decidua parietalis refers to all remaining portions of the decidua [1]. Figure 3
demonstrates the anatomy of the uterus.

fallopian tubes

fundus

uterus
ovary

uterine cavity

cervical canal

body of uterus

cervix

vagina

Figure 3: The uterus (figure adapted [16, 17]). The uterine cavity, fundus, body,
and cervix are demonstrated in this figure.

1.1.2

Uncomplicated vs. Complicated Pregnancies

Many pregnancies progress without complication, resulting in the uncomplicated births
of normally developed and functioning, healthy babies. However, there are many
pregnancies plagued by complications relating to maternal health before and during
pregnancy. Fetal development and environment, including in utero exposures to toxins,
viruses, and adverse maternal environment, can also lead to complications in pregnancy.
Additional complications may arise during delivery or following delivery in the postnatal
period [1].
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1.1.3

Common Complications in Pregnancy

During pregnancy, there are many sources for complications, which may arise from
maternal and/or fetal health status. Some of the more common or serious complications
include maternal and fetal exposures to infectious disease, diabetes mellitus, maternal
hypertension, preeclampsia, intrauterine growth restriction (IUGR), preterm labour, and
pregnancy miscarriage and stillbirth [18]. Conditions such as diabetes, IUGR, and
macrosomia are potentially associated with metabolic dysregulation, which may affect
metabolic regulation in the fetoplacental unit.
Infections with the potential to affect the healthy development and outcome of a
pregnancy include some sexually transmitted infections and infections such as varicella
and rubella [1]. These infections can pass from mother to fetus during pregnancy or can
be passed on to the neonate via the birth canal in a vaginal delivery. Some of the
consequences of maternal infection during pregnancy are a congenital anomaly in the
neonate, low birth weight, miscarriage and stillbirth, and neonatal death. Luckily, many
of these infections can be prevented or treated and managed with appropriate medical
care before and during pregnancy [1, 18].
Diabetes mellitus, a disorder of carbohydrate metabolism, associated with a deficiency in
insulin and characteristic hyperglycemia, can be classified into several types. Some of
the more familiar types are type I, type II, and gestational diabetes.
Gestational diabetes mellitus only occurs during pregnancy, while other types may occur
outside of pregnancy and can persist during pregnancy [1].
Having diabetes mellitus during pregnancy is associated with fetal congenital anomalies
in the skeletal, central nervous, cardiac, renal, and gastrointestinal systems and anomalies
in the umbilical cord, as well as a 15-20% spontaneous abortion rate. These anomalies are
associated with high blood sugar levels, as in hyperglycemia, which disrupts embryonic
organogenesis leading to anomalous organ system development. Diabetes mellitus in
pregnancy may also lead to abnormal growth conditions such as IUGR and macrosomia.
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IUGR is commonly defined as an “estimated fetal weight less than the 10th percentile for
the gestational age”, but this is not the only accepted definition. Unfortunately, the
existence of several definitions for IUGR contributes to a lack of consistency in diagnosis
[1]. Consistency in diagnosis and appropriateness of definitions for the diversity of the
population may also be relevant to the definition and diagnosis of macrosomia in light of
racial, genetic, and sex differences [19, 20].
Fetuses diagnosed with IUGR have increased risk of perinatal mortality and are more
likely across their lifespan to develop conditions such as hypertension, cardiovascular
disease, diabetes mellitus, and obesity. Fetal development of IUGR is more prevalent in
women with hypertension, and preeclampsia is associated with the most severe growth
deficits in terms of maternal factors that may influence fetal growth restriction. IUGR in
fetuses of diabetic mothers is attributed to uteroplacental vascular insufficiency in which
there is less maternal blood reaching the fetus through the placenta carrying critical
nutrients and oxygen needed for normal growth [1].
Macrosomia in a fetus is defined as a fetal weight greater than 4500 grams or a birth
weight above the 90th percentile for gestational age. It may result from fetal
hyperinsulinemia (excessive insulin), as excessive sugars from maternal hyperglycemia
enter the fetal circulatory system through the placenta and stimulate fetal insulin
production [21]. Fetal hyperinsulinemia prompts increased growth of body tissues,
including adipose tissue. Macrosomic fetuses are predisposed to stillbirth and
intrapartum trauma, such as shoulder dystocia [1]. Similar to fetuses with IUGR,
macrosomia predisposes a fetus to cardiovascular and metabolic conditions across their
lifespan, including diabetes mellitus and obesity [3, 20]. Risk factors for developing fetal
macrosomia include maternal diabetes mellitus (type I, II, or gestational), excessive
maternal weight gain, and obesity [1].
Maternal hypertension (high blood pressure) is associated with co-morbidities such as
diabetes mellitus and obesity [22] and may exist before pregnancy or may develop during
pregnancy. If, in addition to hypertension, proteinuria and/or edema develop, we call this
toxaemia of pregnancy or preeclampsia. Preeclampsia can increase the prenatal mortality
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rate and can also develop into the more severe eclampsia involving maternal convulsions
and a significant increase in fetal and maternal mortality [1]. Conditions associated with
preeclampsia include fetal distress, low birth weight, and placental abruption. While the
etiology of preeclampsia is unclear, hormonal, immunologic, and diet-related factors are
considered to be contributors to its development. The proposed etiologic factors are
likely responsible for the placental vascular disease and reduced uteroplacental blood
flow seen in preeclamptic patients, leading to limited oxygen and nutrient delivery to the
fetus via the placenta and ultimately leading to unfavourable outcomes [1].
In summary, there are fetal, maternal, and placental factors intimately intertwined with
the external and internal maternal environment, including diet, which can lead to a
complicated pregnancy.

1.1.4

Importance of Environmental Exposures During Pregnancy

Exposure to toxins and other harmful agents can come from interactions with other
people in the form of viruses and bacteria, as well as from polluted air, contaminated
water, inhaled or ingested substances, and the foods we consume [1, 23-25]. All of these
sources have the potential to negatively impact our health in the short-and long-term,
with pregnant women and their fetuses being no exception. In utero exposure to these
environmental factors can have obvious and disabling effects upon the fetus as in fetal
alcohol syndrome that results from alcohol consumption during pregnancy. They can
also have silent, insidious effects on the fetus, such as the epigenetic changes to
metabolic programming seen with maternal consumption of a poor diet and poor maternal
metabolic health [26].

1.1.4.1

Importance of Maternal Environment

The concept of the developmental origins of health and disease (DOHaD) postulates that
exposure to some environmental factors during crucial periods of growth and
development could have a significant impact on the short- and long-term health of an
individual. This concept suggests that when a developing fetus is exposed to an
inhospitable uterine environment, caused by insults such as poor nutrition, chemicals, or
metabolic and hormonal dysregulation, it responds by developing adaptations to ensure
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its survival in the short term, but also its survival should a similar environment arise later
in life [27].

The quality of the time a fetus spends in utero is critical to its healthy growth and
development and the quality of life of the individual across their lifespan. Since the fetus
is exposed, through the placenta, to the maternal environment, we must consider the
effect that maternal constitutional factors have on the fetus and placenta. Constitutional
factors refer to a basic physiological tendency that affects the etiology of specific
physical conditions, for example, physiological characteristics relating to circulatory and
metabolic function. The maternal diet consumed before and during pregnancy can affect
constitutional factors relating to maternal cardiometabolic health. Previous studies have
shown that both maternal under and overnutrition can result in altered fetoplacental
metabolic programming, perhaps as an adaptive mechanism to prepare for the presumed
adverse environment [28] after birth. Some diets, such as the Western diet (WD), are
calorie-dense and nutritionally deficient and are associated with the development of
overweight and obesity, type II diabetes mellitus (DM), cardiovascular disease, and
deposition of excess dietary energy. This excess dietary energy is stored as fat in ectopic
and cardiometabolically unhealthy fat storage depots in the body, such as intraabdominal
fat stores and intra-organ fat stores (e.g. the storage of excess lipid in the hepatocytes of
the liver). Previous studies have shown that obesity, diabetes mellitus, and chronic
consumption of high fat, high sugar diets, such as the WD, lead to a lipotoxic and
hyperglycemic environment with the potential to impact placental development and
function negatively, and subsequently impact fetal health and programming outcomes
[15, 29].
In summary, the quality of our in utero environment can affect our lifetime health and
quality-of-life trajectory, beginning with the placenta - the interface between maternal
and fetal environments.

1.2

Metabolism

Metabolism refers to the chemical reactions that take place within our bodies to provide
our cells with energy, as required, to maintain homeostasis and sustain life [30].

11

Anabolic metabolism is the generation of larger molecules from smaller subunits, as in
the formation of glycogen from glucose for storage of energy. Catabolic metabolism
refers to the “breakdown” or oxidation of macronutrients, such as fats and carbohydrates,
for the production and use of energy in the form of adenosine triphosphate (ATP) [30].
Energy balance must be reached to achieve homeostasis, meaning that our energy intake
from macronutrients must be in balance with the oxidation of those macronutrients.
While fats are a high-energy fuel, our dietary need for them is low, and most dietary fat
intake is stored in adipose tissue and not oxidized for use as energy unless energy
generation from carbohydrate intake is insufficient to meet daily energy requirements.
Carbohydrates are the primary fuel source for energy production in humans and can be
metabolized to a usable form via several pathways, with the fundamental molecular unit
being glucose. If the composition of an individual’s diet is changed, metabolic flexibility
may allow the body and cells to match the oxidation of fuels to the availability of fuels.
Impairment of this metabolic flexibility may lead to increased dietary energy intake to
maintain homeostasis. An obese state sees excess glucose converted to triglycerides via
lipogenesis and stored in adipocytes. In a state of lipotoxicity, triacylglycerol
accumulates in the lipid droplets of hepatocytes, skeletal muscle, and pancreatic beta
cells. This accumulation in the lipid droplets is a significant factor in the pathogenesis of
insulin resistance, type II DM, and metabolic syndrome [31].

1.2.1

Metabolic Pathways

There are specific metabolic pathways for each type of macronutrient we consume.
Dietary carbohydrates are broken down to glucose in most cases and enter either a nonoxidative or oxidative pathway. The metabolic pathway which will be utilized is
determined by the presence or lack of oxygen, type of cells composing the tissue, and the
intracellular energy level.

In the presence of oxygen, mitochondria, and a cellular need for energy, glucose
oxidation begins with the formation of two pyruvate molecules from a single glucose
molecule via glycolysis. Following this, decarboxylation of pyruvate occurs, producing
two molecules of acetyl coenzyme A (acetyl-CoA), which can then be used in the
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tricarboxylic acid (TCA) cycle. The TCA cycle is also called the citric acid cycle and the
Krebs cycle. This decarboxylation process links glycolysis and the TCA cycle.
Following the TCA cycle, oxidative phosphorylation occurs, from where the majority of
ATP produced via aerobic respiration is derived [30].

In the absence of oxygen, or in cells without mitochondria, the anaerobic respiratory
process of glycolysis occurs. Pyruvate is converted to lactate or alanine via enzymatic
activity to produce, albeit much less efficiently than aerobic respiratory processes,
cellular energy. The process of glycolysis occurs in the cellular cytoplasm. Pyruvate is
converted to lactate via the enzyme, lactate dehydrogenase (LDH). Alanine is derived
from pyruvate in a transamination process that uses the catalyzing enzyme alanine
aminotransferase (ALT).

As mentioned previously, pyruvate can also be converted to acetyl-CoA via the enzyme
pyruvate dehydrogenase (PDH) in the PDH reaction, which occurs in the mitochondria.
Carbon dioxide (CO2), a waste product of this reaction, is in equilibrium with cellular
bicarbonate. Insulin stimulates this reaction and consequently also stimulates the TCA
cycle.
The TCA cycle also occurs within the mitochondria and is a biodegradation process that
begins with the joining of oxaloacetate to acetyl-CoA, forming the TCA cycle
intermediate, citrate. As the cycle continues, multiple intermediates are generated
through enzymatic reactions. The cycle ends where it began with oxaloacetate, having
generated high-energy coenzymes and by-products such as CO2.

The oxidative phosphorylation (OXPHOS) reaction, occurring in the mitochondria,
oxidizes reduced, high-energy coenzymes, such as nicotinamide adenine dinucleotide
(NADH2), via the release of its hydrogen. The energy from hydrogen’s electron is slowly
transferred to oxygen through a series of enzymatic reactions. These enzymes use the
energy released to generate a proton gradient across the inner mitochondrial membrane
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(IMM), which ultimately provides the energy for ATP generation. Water and CO2 are
produced as by-products of OXPHOS [30].
Overall, a theoretical 38 ATP molecules are produced from one glucose molecule via
cellular respiration. In contrast, glycolysis- whether aerobic or anaerobic, produces only
2 ATP molecules per glucose molecule consumed in the process.
Given that these processes are regulated by factors such as insulin and intracellular
energy levels, metabolic conditions that alter these factors can drastically change the
pathway for carbohydrate metabolism and also result in changes to the metabolic
pathways for other macronutrients, such as fats [30].
Recognizing that placental health is critical to fetal development and that the placenta is a
poorly understood organ, it is paramount that we continue to broaden our understanding
of placental development and function - including metabolism, particularly in conditions
of metabolic dysregulation.

1.2.1.1

Pyruvate

In this thesis, the interest was in the metabolic fate of intravenously injected, supraphysiological concentrations of a hyperpolarized, carbon-13-labelled pyruvate (13Clabelled pyruvate) solution (labelled in the C1 position) for two main reasons. First,
understanding that glucose is the primary fuel for our bodies’ cells, metabolic pathways
for carbohydrate metabolism are of critical importance. As has been outlined, pyruvate is
the product of the partial oxidation of glucose during glycolysis, making it an integral
component in the process of cellular energy production from glucose. Second, pyruvate’s
intersection with the LDH reaction, transamination to alanine, and PDH reaction- leading
to the TCA cycle, allows for quick, quantitative probing of these pathways [30]. Figure 4
demonstrates the location in the cell where the 13C1-labelled reactions of interest take
place.
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Figure 4: Metabolic Pathways of Pyruvate [32]. Pyruvate can be converted to
alanine or lactate in the cytoplasm, or it can enter the mitochondria and produce
bicarbonate as a by-product of aerobic cellular respiration pathways. The 13C1 label
is indicated on pyruvate and its metabolites and by-products.

1.3

Metabolic Programming

The predisposition of the offspring of diabetic and/or obese mothers to developing
cardiometabolic conditions later in life is likely the result of early programming of fetal
organ structure and metabolism due to an unfavourable fetal nutritional environment. In
utero exposure to overnutrition (excess dietary glucose and fat) likely alters earlypregnancy processes like epigenetic changes via DNA methylation, placentation, and
fetal organogenesis [28]. These changes result in permanent metabolic abnormalities in
fetal metabolic tissues and organ systems with a subsequent predisposition to
cardiometabolic disease. This process is known as metabolic programming.
As previously discussed, conditions such as diabetes mellitus and obesity can lead to
macrosomic fetuses or fetuses with increased birth weight owing, in part, to an increase
in adipose tissue development. The hyperglycemic maternal environment stimulates the
fetal pancreas to produce insulin, and the fetus subsequently develops hyperinsulinemia,
prompting increased development and deposition of adipose tissue. Interestingly, some
studies have shown that any increase in maternal glucose concentration, even in the
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normal range, is associated linearly with increased fetal adiposity and birthweight [33].
There is also evidence to suggest that these increases in maternal glucose concentration
within the normal range may also predispose the exposed fetus to develop diabetes
mellitus, overweight, and obesity, independent of maternal BMI [34].

1.3.1

Cardiovascular Disease (CVD)

CVD is the number one cause of death worldwide and is composed of a group of
disorders affecting the heart and blood vessels of the body. Coronary heart disease,
cerebrovascular disease, peripheral arterial disease, and deep vein thrombosis are all
examples of CVDs. Risk factors for developing CVD include consumption of a poor
diet, physical inactivity, obesity, tobacco use and genetic factors. Two serious
consequences of CVD are myocardial infarction (heart attack) and cerebrovascular
accident (stroke) most often caused by a narrowing of the blood vessels supplying the
heart or brain due to atherosclerosis. Atherosclerosis is the accumulation of fatty deposits
within the blood vessel walls [35].

1.3.2

Type II Diabetes Mellitus (Type II DM)

Type II DM is a leading cause of death in North America, and the global prevalence of
the disease is rapidly rising. It is characterized by abnormally high levels of glucose in
the blood and reduced sensitivity of the body’s cells to insulin, known as insulin
resistance. Normally, when levels of glucose are increased in the blood, the pancreas is
stimulated to release insulin. Circulating insulin controls glucose levels and drives
glucose from the blood into cells for use as energy or storage once energy needs for the
body are met. With type II DM, the body’s cells are not as responsive to insulin, and
excess glucose remains in the blood. As this resistance to insulin develops, beta cells in
the pancreas produce more insulin to normalize blood glucose levels. Eventually, the
pancreatic beta cells become less capable of responding to fluctuations in blood glucose
levels, and there is a shortage of insulin. This insulin shortage prevents the effective
reduction of glucose levels in the blood.

The aging process and genetic factors involving gene expression are associated with an
increase in the risk of developing type II DM and will exacerbate the metabolic
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dysregulation characteristic of the condition. Other factors such as poor diet, overweight
and obesity, and physical inactivity also increase the risk and exacerbate the metabolic
dysregulation. However, these factors also increase the risk of developing type II DM at
any age. Uncontrolled type II DM can lead to severe health conditions such as CVD and
eye, nerve, and renal damage [36].

1.3.2.1

Fatty Liver Disease

Fatty liver disease refers to the excessive accumulation of lipids within hepatocytes above
5% of the total liver volume. Non-alcoholic fatty liver disease (NAFLD) refers to the
condition where this abnormal accumulation of lipid in the liver cells is not attributable to
alcohol consumption. Instead, the likelihood of developing NAFLD increases with being
overweight or obese, with fat accumulation centred around the waist. Developing
NAFLD is also associated with having type II DM and consuming a diet high in saturated
fat and refined sugars regardless of BMI. As the liver processes sugars and fats from
dietary intake for use as energy for the body, excesses are stored as lipids in the
hepatocytes. This process may lead to enlargement of the liver and, eventually, the
hepatic inflammation and fibrosis characteristic of non-alcoholic steatohepatitis (NASH).
NASH can ultimately lead to cirrhosis of the liver, chronic liver failure requiring
transplant, and liver cancer [37].

1.4

Obesity

Obesity is described as a chronic and progressive disease where excessive fat
accumulates in the body that may harm our health. According to a 2014 health survey, 5
million Canadians were living with obesity, and that number is expected to increase over
the next two decades. The annual direct healthcare cost for obesity-related medical care
is approximately 7 billion dollars, and this cost is expected to rise to 9 billion dollars by
the year 2021 [38].
Obesity is commonly measured using the body mass index (BMI). It is measured by
dividing an individual’s weight in kilograms (kg) by their height in metres squared (m2),
giving a result expressed in kg/m2. This result is then compared to a weight classification
BMI chart to determine an individual’s weight classification. A BMI above 30 kg/m2 is
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generally accepted to represent obesity in the Caucasian population - though this is only a
measure of size and not health. Other factors, such as waist circumference, waist-to-hip
ratio, and the presence of associated co-morbidities, should also be considered when
making a formal medical diagnosis of obesity. A diagnosis of obesity is associated with
the consumption of a Western diet and is also associated with co-morbidities such as type
II diabetes mellitus, hypertension, cardiovascular disease, and infertility [38, 39].

As the rates of obesity in the general population increase, obesity rates in females of
child-bearing age also continue to rise. Obese pregnancies are considered by the medical
community to be “high risk” for serious maternal and fetal complications [40].

1.4.1

Obesity and Pregnancy

Obesity during pregnancy is the most common pre-existing health condition encountered
by health professionals. The risk of developing conditions such as gestational diabetes
mellitus and preeclampsia is increased in obese women when compared to normal-weight
women. As such, fetal congenital anomalies, early spontaneous abortions, and IUGR and
macrosomic fetuses are more likely to occur in obese women. Infertility is also more
prevalent in obese women than in normal BMI women. This increased prevalence may be
due to changes in the menstrual cycle, the quality of oocytes ovulated from the ovaries,
and an unfavourable endometrial environment for implantation and development of the
conceptus within the uterus [19].
Obesity in pregnancy is implicated in long-term effects on the fetus. Early pregnancy
alterations to fetoplacental metabolic programming can increase the risk in the offspring
of developing conditions such as type II diabetes mellitus, cardiovascular disease, and
obesity throughout their lifespan. This increased risk seems to be the result of metabolic
dyregulation in the maternal environment. Increased insulin resistance results in
decreased uptake of glucose into the tissues for energy metabolism. Subsequent
increases in lipolysis for energy metabolism contribute to a lipotoxic environment and
represent a dysregulated metabolic state. It is thought that this metabolic dysregulation is
a contributing factor to the epigenetic changes in fetoplacental metabolic programming
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and may even be damaging to the placental tissues, affecting the development and
function of the placenta [19].

1.5

Western Diet

The term “diet” refers to the types of food habitually consumed by an individual or by a
whole community. The foods we consume provide us with energy and nutrients, such as
glucose and vitamins and minerals that help our bodies to maintain homeostasis. Our
bodies require energy and nutrients derived from the foods we consume, to maintain
proper growth and functioning of our organ systems and also, in times of stress, illness,
or damage to protect us from harmful agents and repair damaged cells.
The quality and composition of one’s diet are paramount to our health and a significant
factor in whether or not we develop many largely preventable diseases, such as
cardiovascular disease or type II diabetes mellitus. A nutritionally complete and
metabolically healthy diet is composed mostly of a wide variety of fruits, vegetables,
legumes, and complex carbohydrates with relatively small amounts of meat, seafood and
fish, and dairy. This type of nutritionally rich diet provides us with the nutrients and
metabolically healthy energy sources we require while being naturally low in saturated
fats and simple carbohydrates, which are detrimental to our metabolic function [41, 42].
Over the last few decades, there has been an increasing trend towards highly processed,
fast-food-type diets in many developed countries that are strongly associated with the
current obesity epidemic in North America. These diets are commonly referred to as the
Standard American diet and the Western diet. These diets are widely available and
widely consumed intermittently and habitually.
Typically, a WD is high in fat content, high in refined sugars, and high in red meat
content while being low in dietary fibre and having very few fruits, vegetables, and
legumes. Overall, this is a nutritionally poor, calorically dense diet that is not compatible
with our energy and nutritional requirements. Habitual consumption of a WD is strongly
associated with obesity, cardiovascular disease, and type II DM [43, 44].
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Again, just as consumption of a WD has the potential to impact the health of nonpregnant adults and children negatively, it will also likely impact the fetoplacental unit in
a critical period of growth and development.

1.5.1

Western Diet for an Animal Model of Pregnancy

In this thesis, pregnant guinea pigs were used as an animal model for the human
fetoplacental unit. Either a control diet (CD) or a Western diet was fed ad libitum to the
pregnant guinea pigs for their lifetime. Both the control and Western diet feeds for the
guinea pigs were pelleted and soy-based, with the WD being energy-dense. Percentages
of dietary protein, carbohydrate, and fats (PUFAs- polyunsaturated fatty acids, MUFAsmonounsaturated fatty acids, and SFAs- saturated fatty acids) that compose the two diets
are designed to mimic, as closely as possible, a cardiometabolically healthy diet as a
control and a Western diet for a guinea pig model of pregnancy [45, 46]. Figure 5
illustrates the components of the control and Western diets.

Figure 5: This figure demonstrates the percentage composition of carbohydrates,
fats, and protein in the control and Western diets [7, 45].

1.6

Guinea Pig (GP) Model of Pregnancy

There are several possible models of pregnancy. Most notably, sheep and rodents have
often been preferred as a model because of their similarities to the human gestational
process and are, therefore, most apt to provide information that can be translated to the
human gestational period [47]. However, these models have several disadvantages.
Translational research concerning the developmental origins of health and disease
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requires a small animal model with a relatively short life span compared to humans.
Sheep take a longer time to reach maturity and present more significant challenges
concerning housing and management compared to other small animal models. Rats and
mice, while more suitable than sheep in terms of size, complete key stages of
development post-natally in contrast to the prenatal development seen in humans.
Additionally, mice and rats tend to have large litters of 8-12 pups- a characteristic
considered undesirable for clinical translation of research. Guinea pigs (Cavia
porcellus), another type of rodent, are small animals, have relatively smaller litter sizes of
1-5 pups, are prenatal developers and have also emerged as a suitable model of
pregnancy given their many structural and functional similarities to humans, as well as
similarities in their physiological response to insults [47].
While the gestational period of a guinea pig (GP) is ~69-71 days compared to the ~40week gestation of a human fetus, its fetal developmental timeline and process is broadly
similar to that seen in the human fetus. For example, the fetal GP accumulates both
brown and white adipose tissue in utero and has a high total fat content at birth, unlike
other rodents and sheep. Another critical similarity to humans is the placental structure
and function. The GP placenta is haemomonochorial, meaning that there is a single layer
of chorionic cells separating maternal and fetal circulation of red blood cells. This type
of separation between maternal and fetal blood circulation is analogous to the
haemochorial placenta seen in humans. Also similar to the human placenta, the GP
placenta has deep decidual invasion and similar cell columns of the anchoring chorionic
villi in the subplacenta, among other structural similarities. Other rodent models lack the
deep decidual invasion by the placenta seen in guinea pig and human pregnancy [47].
Functionally, the placenta in GPs has similar metabolism to humans and supports the
pregnancy through the provision of progesterone throughout the major part of pregnancy,
similar to humans but unlike mice, rats, and sheep, who rely on progesterone produced
from the ovaries to maintain pregnancy. Because exposures to insults, such as an adverse
maternal environment, can occur at a similar developmental stage, in a similar in utero
environment, and with similar physiological responses to insults, the pregnant GP is
considered to be an excellent model of human pregnancy [47].
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1.6.1

Western Diet Association

It has been established that the metabolic dysregulation seen with obesity during
pregnancy can alter fetoplacental processes leading to unfavourable outcomes of
pregnancy in the short and long term. The ongoing rise in rates of overweight and
obesity in the developed world is strongly associated with the consumption of a Western
diet, high in saturated fats and refined sugars and low in nutritional quality. It is
acknowledged in the literature that while there are relatively fewer studies focussed on
the effects of a nutritionally poor, calorie-dense diet on the fetoplacental unit, this type of
diet likely exerts an independent effect on the fetoplacental unit regardless of other
factors [26].

1.7
Current Monitoring Methods of Fetoplacental
Health
Currently, clinical monitoring of the health of a pregnancy is centred around a patient
interview and manual examination by a specialized health care provider. Referral for
laboratory tests and ultrasound examinations are routine protocol or can be ordered as
needed should a pathological condition be suspected [48]. The use of magnetic
resonance imaging (MRI) in pregnancy is possible and can contribute valuable
information, but clinical use of MRI in pregnancy is still uncommon. Imaging modalities
such as x-ray are not recommended for use in pregnancy, except perhaps in
extraordinary, emergency cases, owing to the increased risk of unfavourable outcomes
from exposure to ionizing radiation in the fetus [49].

1.7.1

Diagnostic Medical Ultrasound

Diagnostic medical ultrasound is a widely used, non-invasive imaging modality that
employs non-ionizing energy in the form of sound waves from 2-15 MHz in frequency to
generate high quality, medically diagnostic images of the internal structures and organs
of the human body. Diagnostic medical ultrasound is commonly used for the
management of uncomplicated and complicated pregnancies alike. Some advantages of
diagnostic medical ultrasound include its wide availability, relatively low cost, use of
non-ionizing energy, relatively high spatial and temporal resolution, and its real-time
imaging capabilities [50]. Through the use of ultrasound in pregnancy, health care
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providers can interpret B-mode anatomical images to identify normal and pathological
findings and make accurate quantitative measurements regarding the size and location of
fetal and maternal structures. They can also accurately estimate gestational age and fetal
weight and accurately estimate functional parameters such as blood flow velocity,
vascular resistance, and vascular pulsatility and waveforms using Doppler ultrasound [1,
50].
Ultrasound also has some disadvantages. It is highly operator dependent; it clinically uses
2-D measurements for image interpretation rather than 3-D volume measurements, which
more accurately reflect the ground truth [51, 52]; and it provides only limited in vivo
functional information and no direct metabolic information.

1.7.2

Fetoplacental Diagnostic Medical Ultrasound Assessment

The fetoplacental unit is readily assessed using diagnostic medical ultrasound. As
pregnancy is by nature a process of growth and development, the routine examination
protocol and interpretation of image characteristics changes with gestational age. The
echogenicity and tissue texture of the placenta are qualitatively assessed, and the fetal
organs and structures are assessed for abnormalities. Some other common qualitative
characteristics, such as the placental location in the uterus and fetal orientation, situs, and
presentation, are also documented. Quantitative measurements include the crown-rump
length (CRL), cervical length, distance from the placental edge to the internal os of the
cervix, abdominal circumference (AC), fetal heart rate (FHR), biparietal diameter (BPD),
femur length (FL), amniotic fluid index (AFI), and umbilical, ductus venosus, and middle
cerebral artery (MCA) Doppler measurements. Late pregnancy assessment via
ultrasound also includes the assessment of biophysical parameters, such as gross and fine
fetal motor movements and attempted respiratory movements [1]. All of these
assessments are made in an attempt to monitor and understand fetoplacental health, but
much more information, including metabolic and tissue volume information, is required
that is simply not available with current ultrasound technology and clinical protocols.
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1.7.3

Magnetic Resonance Imaging

MRI is an imaging modality that typically relies on the signal generated from the
displacement and return to thermal equilibrium of the nucleus of a hydrogen atom for its
image contrast. However, imaging of nuclei other than hydrogen is possible. Signal
generation is achieved by aligning the nuclei in the main magnetic field (B0), with
subsequent and repeated disruptions to their alignment by a radio-frequency (RF) pulse
(B1). The application of an RF pulse causes displacement of protons away from the zdirection and toward the x-y plane. The z-vector represents, by convention, the direction
of the B0 magnetic field. Following the RF pulse, the protons return to thermal
equilibrium in a process known as relaxation.
Longitudinal relaxation refers to the regrowth of magnetization in the z-direction and its
return to equilibrium. The length of time it takes to achieve equilibrium is equal to 5xT1.
T1 is an intrinsic characteristic of the substance or tissue being imaged. Transverse
relaxation refers to the decay of magnetization away from the y- and x-directions. The
length of time this takes is known as T2 and T2*. Transverse relaxation time is affected
by interactions with nearby protons, and T2* is also affected by inhomogeneities in the
magnetic field. While T2 is an intrinsic characteristic of the imaged substance, T2* is
subject to extrinsic factors such as local field inhomogeneity. Generally, these tissue
characteristics form the basis for the multitude of image contrasts that are possible with
MRI [53].

1.7.3.1

Advantages/Disadvantages of MRI

MRI is a complex, diverse, and flexible imaging modality with many benefits and some
disadvantages relative to other imaging modalities. Some disadvantages include high
cost [54], lack of availability, lack of expertise - specifically in fetal imaging, long
examination time, sensitivity to motion [55], and suitability for all patient populations in
terms of patient body habitus and patient safety in a strong magnetic field. Some benefits
include a multitude of available image contrasts with adjustable imaging parameters that
allow the operator or physician to tailor the acquisition to their needs; unsurpassed tissue
contrast; the capability for reliable 3-D volume acquisitions; its use of non-ionizing
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energy; its ability to provide structural and functional information about our bodies,
including metabolism; and its multinuclear capabilities [53, 56, 57].
While diagnostic medical ultrasound remains the most common imaging modality
employed throughout pregnancy, the use of MRI- specifically hyperpolarized carbon-13
(13C) MRI has the potential to provide complementary in vivo metabolic information that
could serve as a biomarker for fetoplacental health.

1.7.3.2

Anatomical Imaging

As previously mentioned, MRI can generate many different image contrasts. Some of
these include diffusion-weighted imaging (DWI), proton density (PD) weighting, T2weighted (T2-w), and T1-weighted (T1-w). The weighting of an image contrast refers to
the tissue characteristics that are allowed to, by manipulation of imaging parameters,
dominate the resulting image signal intensity. For example, in a T1-w image, parameters
such as repetition time (TR) and echo time (TE) can be adjusted to capitalize on the
effects of T1 while minimizing the effects of T2 on image contrast. Typically, T1-w
images provide high resolution, detailed anatomical information, including visualization
of pathology. T2-w images provide the same type of information as T1-w images, but are
generated mostly from T2 tissue characteristics and are complementary to T1-w images
[53].

1.7.3.3

Carbon-13 (13C) and MRI

While conventional MRI utilizes the proton within the nucleus of a hydrogen atom to
generate a signal, it is possible to generate a signal from the protons in the nucleus of
other elements, such as carbon, which forms the backbone of many biological molecules.
The natural abundance of carbon-12 (12C) in tissues is 98.93%, similar to the abundance
of hydrogen (1H) at 99.98% [58]. However, 12C is not visible on MRI due to its lack of
nuclear spin, but its isotope, 13C, is visible and has previously been exploited in research
on cancer metabolism. MR imaging with 13C has three main limitations. First, in the
body, the atomic concentration of carbon is approximately 1/5th of the atomic
concentration of hydrogen. Therefore, the signal that can be obtained from carbon can be
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no more than 1/5th of the signal that can be obtained from hydrogen, since there are 1/5th
as many carbon nuclei as hydrogen nuclei present in the body to generate a signal.
Second, the natural abundance of 13C in the body is extremely low, at 1.11%. Since the
MRI signal is proportional to the number of 13C nuclei in an image voxel, the signal
detected from 13C is substantially lower than the signal that can be detected from 1H.
Finally, the signal obtained is proportional to the gyromagnetic ratio, which for 13C, is
roughly one-quarter of the gyromagnetic ratio of 1H (Table 1). Again, this results in very
low levels of signal from 13C and makes in vivo MR imaging very challenging because
the 13C signal relative to 1H is approximately equal to 1/5 x 1/100 x 1/4 of the 1H signal
or 0.05% of the 1H signal [59].
Table 1: Comparison between 1H and 13C natural abundance, gyromagnetic ratio,
and relative signal strength.
1H

13C

Natural Abundance

99.98%

1.11%

Gyromagnetic Ratio

42.58

10.71

1

0.0005

NUCLEUS

(MHz/T)
Relative Signal Strength

1.7.3.4

Hyperpolarized 13C Imaging

Even though MR has limited sensitivity to endogenous 13C, methods can still be
employed to take advantage of the biological information that can be obtained from 13C
MRI. First, rather than depending on endogenous 13C to generate signal, highly-enriched,
13

C-labelled molecules such as pyruvate can be introduced to the biological system.

Typically, supra-physiological amounts of the labelled agent are required for distribution
throughout the tissues of interest. Additionally, the enriched and labelled agent can be
hyperpolarized. Hyperpolarization is the process of enhancing the magnetization of a
sample. It is achieved by increasing the degree of alignment of the sample’s nuclei within
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the magnetic field beyond the degree of alignment possible at thermal equilibrium [59].
Though there are a few methods of hyperpolarization, dynamic nuclear polarization
(DNP) is used in this thesis.

1.7.3.4.1

Dynamic Nuclear Polarization (DNP)

DNP is the transfer of spin polarization from highly polarized electrons to the
surrounding nuclei. This polarization is achieved by irradiating the sample containing
100%-enriched 13C molecules with microwaves at low temperatures (1.4K) and high
magnetic field strength (3.35T). This process yields a frozen hyperpolarized sample.
The frozen hyperpolarized solution must then be warmed rapidly to near body
temperature by a process referred to as dissolution before in vivo administration.
Recalling that the MRI signal generated from endogenous, unpolarized 13C is
approximately 0.05% of the signal that can be generated from 1H, DNP increases the MRI
signal of hyperpolarized 13C solutions by 10,000-fold when compared to the signal
possible at thermal equilibrium. Therefore, the process of hyperpolarization via DNP
increases the signal to levels comparable to 1H MRI, despite the small injected volume of
the hyperpolarised sample, and makes 13C MRI feasible [59].

1.7.3.4.2

[1-13C] Pyruvate

While it is possible to label most biological molecules with 13C for use as a
hyperpolarized 13C probe, some practical considerations need to be reviewed. First, the
T1 value of the hyperpolarized probe must be long enough to maintain magnetization for
MRI before the signal decays away to thermal equilibrium. Second, as a probe of in vivo
metabolism, the hyperpolarized solution must be rapidly administered to undergo
metabolism in the tissue of interest before imaging begins. As such, the T1 value of the
13

C nuclei itself is of critical importance. In 13C-labelled pyruvate, the T1 is on the order

of tens of seconds. By the time 3xT1 has elapsed, 95% of the signal has already been lost.
Therefore, the sample of hyperpolarized solution must be transported to the MRI unit,
injected, distributed to tissues of interest via the vasculature, and metabolized quickly to
take full advantage of the signal generated by a hyperpolarized 13C probe. Lastly, the
position of the 13C-label on the carbon-based molecule has implications for the observed
chemical shift of the molecule and alters the metabolic pathways that can be probed.
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[1-13C] pyruvate (13C label on the C1 carbon position of pyruvate) is the hyperpolarized
13

C probe most commonly used for in vivo metabolic imaging as it addresses the

challenges listed above. The C1 of pyruvate has a T1 of approximately 65s at 3T. This T1
is relatively long and ensures sufficient magnetization of the 13C-labelled pyruvate is
available for signal generation during administration and metabolism. Next, pyruvate is a
crucial metabolite at the intersection of several critical metabolic pathways. In addition to
these properties, pyruvate with a single 13C label has a single spectral peak for each of its
metabolites that are well-separated by chemical shift. These separated single peaks allow
for accurate quantification of metabolic conversions from pyruvate to its metabolites.
The use of [1-13C] pyruvate permits the probing of glycolysis as it pertains to the
conversion of pyruvate to lactate, alanine, and acetyl-CoA via the PDH reaction with CO2
as a by-product. It does not, however, allow for probing of the TCA cycle because the
[1-13C] label does not transfer to the metabolites involved in the TCA cycle as the
labelled pyruvate is metabolized. This lack of label transfer to metabolites makes the
TCA cycle invisible when using a [1-13C] pyruvate solution [59]. To probe the TCA
cycle, the C2 of pyruvate must possess a 13C label [60].
1.7.3.4.3

Hyperpolarized MRI Sequence- BB IDEAL

There are many different types of MRI sequences designed to capture specific
information. To gather metabolic information using a 13C hyperpolarized solution, a
broadband iterative decomposition of water and fat with echo asymmetry and leastsquares estimation (BB IDEAL) acquisition and reconstruction has proven to be
effective. BB IDEAL is a chemical-shift-encoded sequence that is a variation on the
IDEAL sequence, which ordinarily quantifies the fat and water content of tissues. For
this adaptation, instead of separating the signal from fat and water, the BB IDEAL
reconstruction separates the signal coming from pyruvate, lactate, alanine, and
bicarbonate based on their known chemical shift using an expanded Dixon method. BB
IDEAL MR is a gradient-echo sequence with a spiral-pattern, center-out collection of kspace data that provides 3-D proton density (PD) weighted images [61].
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1.7.3.4.4

Area Under the Curve (AUC)

The AUC is a data analysis method that permits the quantification of rates of metabolism
of hyperpolarised substrates. For this thesis, the AUC is the sum-over-time of the PDweighted signal for each respective metabolite in a time-resolved data set. The ratio of
the AUC for pyruvate to the AUC of each metabolite provides the lactate-, alanine-, and
bicarbonate-to-pyruvate ratios - the LPR, APR, and BPR, respectively. These AUC
ratios represent the relative signal intensity of each metabolite throughout the BB IDEAL
MR acquisition. These normalized AUC ratios are directly proportional to the rate
constants of conversion from pyruvate to lactate, alanine, and bicarbonate, given as the
kPL, kPA, and kPB, respectively [62]. This proportionality exists because the metabolic
reactions under examination represent first-order reactions in terms of enzymatic activity.
A first-order reaction means that the concentration of the catalyzing enzyme is
proportional to the first power of substrate concentration [catalyzing enzyme] ∝
[substrate1]. Thus, the amount of enzymatic activity and resultant metabolite production
(i.e., lactate, alanine, bicarbonate) is not limited by the amount of substrate (i.e.,
pyruvate) present [63].

1.8

Objective and Hypothesis

The objective of this thesis was to investigate the relationship between maternal Western
diet consumption and placental metabolic function and to quantify metabolic function
using hyperpolarized 13C MRI in a guinea pig model of pregnancy.

This thesis postulates that lifelong maternal consumption of a Western diet perturbs
placental metabolic function, resulting in an increase in the conversion rate of pyruvate to
lactate and alanine (kPL and kPA, respectively) and a decrease in the conversion rate of
pyruvate to bicarbonate (kPB).
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Chapter 2

2

Assessing Mid-pregnancy Placental Metabolism and
Physical Characteristics in Guinea Pigs Fed a Lifelong
Western Diet

In this study, conventional MRI and hyperpolarized 13C MRI were used to assess midpregnancy placental metabolism, appearance, and volume. Pregnant sows were fed either
a control or Western diet to ascertain the effects of diet consumption on placental
metabolism and physical characteristics.

2.1 Introduction
Throughout the gestational period, pregnancies can develop complications, which can
negatively impact the fetoplacental unit. Some of these complications are related to in
utero environmental exposures of the fetoplacental unit to external toxins or an
unfavourable maternal environment. One factor that has the potential to affect the
condition of the maternal environment, which ultimately impacts the fetal environment, is
the consumption of a Western diet [64].
When challenged, cellular metabolic flexibility enables cells to adaptively utilize
metabolic pathways to maintain energy status and physiological function [31]. Numerous
disease states see metabolic flexibility as a hallmark of the physiological and pathological
alterations affecting cellular function and survival through induction of a “glycolytic
shift.” This shift means cells will favour the production of ATP by glycolysis instead of
ATP production via oxidative phosphorylation [65]. Pyruvate is a central metabolite for
cellular metabolism. It is produced in the cytoplasm, mainly by glycolysis, and exists in
equilibrium with alanine and lactate [30].
Consumption of a WD, which is high in saturated fat and refined sugar, during pregnancy
is associated with metabolic and mitochondrial dysregulation in maternal and fetal
placental compartments at term [66]. This study sought to investigate if a glycolytic
shift, early in pregnancy, might exist and possibly underlie late-pregnancy metabolic
dysregulation. Hyperpolarized 13C MRI techniques have been used to image metabolism
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in pregnancy[67], but only normal pregnancies were investigated. Hyperpolarized 13C
MRI techniques have previously been successfully used to identify a glycolytic shift in
human prostate cancer studies [68]. If a shift can be identified, technologies, such as
hyperpolarized 13C MRI, could provide a useful diagnostic tool in determining the
severity of placental dysfunction and also help to understand the efficacy of treatments
aimed at modulating the negative impacts of poor diet during pregnancy.
The development over gestation of placental metabolic processes, particularly pyruvate
metabolism, are currently poorly understood. As such, this study aimed to quantify
changes in the rate of conversion of pyruvate to lactate (kPL), alanine (kPA), and
bicarbonate (kPB) in a pregnant guinea pig (GP) model. It was postulated that lifelong
consumption of a WD, in conjunction with pregnancy, would result in an increased midpregnancy placental kPL and kPA and a decreased placental kPB. This hypothesis was
derived from the idea that consumption of a WD and subsequent creation of a lipotoxic
environment may lead to oxidative damage to the placental mitochondria. This damage
may alter metabolic processes occurring in the mitochondria, such as the TCA cycle (part
of aerobic cellular respiration). Damage to the mechanisms for aerobic cellular
respiration may lead to increases in glycolytic activity (increases in lactate and alanine
production) and decreases in aerobic cellular respiratory activity (decreases in
bicarbonate) [14, 15]. Identifying alterations in placental metabolism may serve as a
biomarker for fetoplacental metabolic health and provide us with knowledge regarding
WD-exposed pregnancies not previously available.

Methods

2.2
2.2.1

Guinea Pig Model of Pregnancy

Data from 46 fetoplacental units from 15 pregnant sows, fed either a control or a Western
diet lifelong, were collected. These sows were second-generation animals carrying their
first viable pregnancies determined using diagnostic medical ultrasound. In this study,
there were 33 fetoplacental units from 11 WD-fed sows and 13 fetoplacental units from 4
CD-fed sows.
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2.2.2

Image Collection

Each sow underwent MRI at 33 days gestation (~mid term) with a term pregnancy being
approximately 69 days. Animals were fasted 2 hours before MRI to ensure a similar
metabolic state between sows. They were then given a 0.01mg/kg (body weight) dose of
glycopyrrolate 30 minutes before MRI via subcutaneous injection to reduce saliva
production by the sow and reduce the risk of aspiration when under anaesthetic.
Following the administration of glycopyrrolate, the GPs were anaesthetized using
isoflurane. Anaesthesia was induced using a constant flow of 4.5% isoflurane and
maintained with 1.5-2.5% isoflurane. The GPs were administered 2L/min of 100% O2 for
the duration of the experiment (~2.5 hours). An intravenous catheter was inserted into
the saphenous vein of the left, hind foot to maintain vascular access for the injection of
the hyperpolarized pyruvate solution.
The sows were secured in the prone position on a custom-built bed for MRI for the
duration of the experiment and had their vital signs monitored using an animal
monitoring kit (Small Animal Instruments, Inc.), containing a rectal thermometer, pulse
oximeter, ECG leads, and respiratory pillow. The heart rate and electrocardiogram
waveform, respiratory rate and respiratory waveform, percentage of oxygen saturation,
the temperature in degrees Celsius were continuously observed and recorded periodically
during the MRI scan. A single ECG lead, coated with electrode gel, was secured to the
left and right front paws. The respiratory pillow was placed under the sows on their
ventral aspect, near the location of the respiratory diaphragm, and a pulse oximeter was
secured to the right hind foot. The lubricated thermometer was inserted rectally. The
body temperature of the sows was maintained via a water-bath system containing two
water pads with re-circulated heated water flowing through them. One pad was secured
to the custom-built bed, underneath the sows, and the second pad was secured to the
dorsal aspect of the sows. Foam earplugs were inserted into the right and left ear canals,
and protective lubricant was applied to both eyes.
A series of MRI images were collected using a 3 T MRI (General Electric MR750),
including T1-w anatomical and BB IDEAL metabolic images. Following MRI, the sows
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were allowed to recover and were humanely euthanized via CO2 chamber ~48 hours postMRI for the collection of fetal and maternal tissues for correlation.
The anatomical images were acquired with standard 1H MRI, using a 32-coil cardiac
array for data reception. The posterior half of the cardiac array was placed under the
custom-built bed, and the anterior half of the cardiac array was placed over a plastic
dome covering the sow and custom-built bed. A 3-D T1-w spoiled gradient echo (SPGR)
sequence was used to collect anatomical images with a scan time of ~8 minutes. These
images served as an anatomical reference for manual segmentation of the placentae. This
sequence had the following parameters as seen in Table 2: TR=5.1ms, TE=2.4ms,
resolution=0.88mm, matrix=320 x 320mm, FOV=28 x 19.6cm. The field of view (FOV)
was centred over the sow’s abdominal region, ensuring visualization of all fetoplacental
units.
Table 2: Summary of T1-weighted imaging parameters.
IMAGING

TR (ms)

TE (ms)

FOV (cm) Matrix

PARAMETERS
T1-weighted

5.1

2.4

Images

2.2.2.1

28 x 19.6

Resolution

(mm)

(mm)

320 x 320

0.9
isotropic

Metabolic Images

Metabolic images were collected using a custom 13C birdcage coil (Morris Instruments).
Before placing the sow in the 13C coil, the 13C coil was calibrated using the 13C acetate
phantom signal and a free induction decay (FID) sequence to ensure visualization of the
13

C signal. The 13C coil was then replaced with the 1H array for anatomical imaging.

Following anatomical imaging, the 1H array was switched out for the 13C coil in
preparation for the injection of the hyperpolarized [1-13C] pyruvate solution. The 13C coil
was once again calibrated, this time using the signal from endogenous 13C in the sow to
achieve the most accurate calibration. Loading the coil with the pregnant sow might have
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altered the coil’s calibration, so re-calibrating ensured the most accurate calibration for
data collection. Following the preparation and administration of the hyperpolarized [113

C] pyruvate solution (see details in Section 2.2.3), metabolic images were acquired [61,

67].
A 3-D broadband IDEAL MRI sequence with a hybrid flip angle (HFA) scheme [69] was
used to collect metabolic images for metabolite quantification and localization within the
placentae. Over a 50 second scan time, seven metabolic images with 14 slices each were
acquired at 7.5s intervals, using the acquisition parameters in Table 3. The FOV was
centred over the sow’s abdominal area to ensure the inclusion of all fetoplacental units.
Table 4 contains the flip angle (FA) for each metabolite at each time point.
Table 3: Summary of the imaging parameters for the BB IDEAL images.
IMAGING

TR

TE1

∆TE ETL FOV Matrix Slice

PARAMETERS (ms) (ms)

(cm)

(mm)

(ms)

BB IDEAL
Images

16

4.5

1.1

Resolution

Thickness (mm)
(mm)

4

20

24 x
24

8.5

8.3 inplane
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Table 4: Summary of hybrid flip angle scheme for metabolic image acquisition.
HYBRID

Time

Time

Time

Time

Time

Time

Time

FLIP

Point 1

Point 2

Point 3

Point 4

Point 5

Point 6

Point 7

FA

FA

FA

FA

FA

FA

FA

(deg)

(deg)

(deg)

(deg)

(deg)

(deg)

(deg)

Pyruvate

1.2

1.5

2

2.8

4.6

10

68

Lactate

1.2

1.6

2.1

3.2

5.4

13.4

88

Alanine

1.2

1.6

2.1

3.2

5.4

13.4

88

Bicarbonate 1.2

1.6

2.3

3.6

6.6

20.8

88

ANGLE
SCHEME

2.2.3

Hyperpolarized Injection

Following anatomical imaging, a 250mM hyperpolarized [1-13C] pyruvate solution,
prepared via dynamic nuclear polarization using a Hypersense 3.35 T polarizer (Oxford
Instruments), was dispensed into a flask. The weight-based dose (75mg/kg body weight),
plus ~0.2mL, was drawn up in a 5mL syringe by M-E.E and transported to the MRI
scanner (~30s) by L.M, L.S, or T.W. The pyruvate solution was then injected into the
sow as a bolus through the previously inserted intravenous catheter over an ~12s period
by L.F-W. The BB IDEAL imaging sequence was initiated manually using the key-pad
at the bore of the magnet 7.5s after the injection began. Metabolic images were collected
over the 50s scan time. The excess solution collected in the syringe was then flushed
through the IV set with 0.9% saline, while an FID sequence (~1min scan time) was
initiated to ensure in vivo hyperpolarization of the 13C signal.
The excess solution remaining in the flask after dispensation from the polarizer was
drawn up in a separate 3mL syringe by M-E.E immediately following the collection of
the weight-based dose, plus ~0.2mL. The excess solution was injected into the MQC
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(Oxford Instruments) to ensure adequate polarization.

2.2.4

Analysis

Placental volume and characteristics, as well as litter size analyses, were completed using
the T1-w image acquisitions. The number of fetoplacental units visualized on MRI was
determined using the T1-w images and recorded on the experimental protocol form. BB
IDEAL image acquisitions were used to analyze metabolic data. The pregnancy loss rate
was determined using post-MRI collections data. However, in some instances, loss rate
data was taken before fetal collections when the pregnancy was lost post-MRI but precollection. Pregnancy loss was confirmed either by ultrasound or visible discharge of the
products of conception. The incidence of abnormal placentae was determined using the
placental score (see Section 2.2.4.1.1). Nested statistical analyses were performed on the
collected data using R (version 4.0.0) [70]. Only placentae having undergone successful
HFA-metabolic MRI were included in the analyses.

2.2.4.1

T1-w Analysis

M-E.E performed manual, full-volume segmentation of each placenta for placental
localization using the collected T1-w anatomical images and 3D Slicer (version 4.9.0)
[71-74]. For each placenta, the volume, location relative to the maternal anatomy, and
placental characteristics (see Section 2.2.4.1.1 below) were recorded.

2.2.4.1.1

Placental Characteristics and Scoring Analysis

The placental appearance was qualitatively evaluated and scored using the set of 6 binary
criteria (score of zero or 1 for each criterion) in Table 5. These criteria were based on
observable physical characteristics typical of normally-developed and healthy placentae
in humans [1] and as observed in the majority of the CD-exposed placentae in the GPs.
The following criteria were evaluated for each placenta. The overall visibility (Table 5:
characteristic i) of each placenta was noted. A score of zero was given if the placenta
was readily identified, and all aspects of the placenta were clearly visible and
differentiated from surrounding tissues. A score of 1 was given if the placenta was
poorly visualized and differentiated from surrounding tissue.
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Next, placental border differentiation (Table 5: characteristic ii) was evaluated. The
“border” refers to where the outer placental membrane meets the internal placental
parenchyma. Placentae with well-differentiated placental borders were assigned a score
of zero, and poorly differentiated placental borders were assigned a score of 1.
The third criterion evaluated the smoothness and regularity of the placental border (Table
5: characteristic iii). Smooth and regular borders were given a score of zero, and
irregular or lobular borders were given a score of 1.
The next criterion evaluated the homogeneity of the placental parenchyma (Table 5:
characteristic iv). Placental parenchyma observed to be homogenous was given a score
of zero, and heterogeneous placental parenchyma was given a score of 1.
The fifth criterion evaluated the homogeneity of the MRI signal intensity between the
placental parenchyma and border (Table 5: characteristic v). A score of zero was
assigned if the observable difference in signal intensity between the placental
parenchyma and border was non-existent or small. A score of 1 was assigned if the signal
intensity of the placental border was perceived as being markedly hyperintense compared
to the placental parenchyma.
The final criterion assessed was based on whether or not a complete fetoplacental unit
(fetus and placenta) was readily discernable (Table 5: characteristic vi). Readily
discernable fetoplacental units were given a score of zero. In cases where only a placenta
could be visualized, a score of 1 was given. A score of zero indicated a “normal”
appearing placenta or fetoplacental unit for that particular criterion. A score of 1
indicated a deviation from “normal” or an “abnormal” appearing placenta or fetoplacental
unit for that specific criterion.
The maximum placental score was six, and the minimum placental score was zero. An
overall placental score of zero indicated a normal-appearing fetoplacental unit. Any
overall placental score of 1 or more indicated the presence of abnormal observable
physical characteristics. Table 5 summarizes the scoring characteristics and the method
of scoring.
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Table 5: Summary of placental characteristics and scoring method.
PLACENTAL

i

ii

iii

iv

v

vi

Readily

Differentiated

Regular

Homogeneous

Homogeneous

Yes

Poor

Irregular

Heterogeneous

Heterogeneous

No

SCORING AND
CHARACTERISTICS
Score=0

visible

Score=1

Poor
visibility

differentiation

Description

Overall

Placental

Placental

Placental

Homogeneity

Identification

visibility

border

border

parenchyma

between

of complete

differentiation

regularity

homogeneity

placental

fetoplacental

parenchyma and

unit

border

2.2.4.2

BB IDEAL Analysis

The metabolic images were reconstructed from the raw data set using the BB IDEAL
reconstruction and MATLAB program (version R2019a) [75]. The placental volume
segmentations generated from the T1-w images were then transferred to and overlaid on
the reconstructed metabolic images to localize metabolite signals to the placentae. The
AUC for pyruvate, alanine, lactate, and bicarbonate was calculated from the flip angleadjusted mean metabolite signal intensities (𝑆𝐼𝐹𝐴 ) in each placental volume at each of the
seven time-points 𝑡 using Microsoft Excel (2011) according to Equation 1:
Equation 1:
𝐴𝑈𝐶𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒 = ∑ 𝑆𝐼𝐹𝐴 (𝑡)
𝑡

Equation 2:
𝑺𝑰𝑭𝑨 =

𝑹𝒂𝒘 𝑴𝒆𝒂𝒏 𝑴𝒆𝒕𝒂𝒃𝒐𝒍𝒊𝒕𝒆 𝑺𝑰
𝐬𝐢𝐧(𝑭𝑨)

38

Though the AUC assumes a constant flip angle, Equation 2 corrects the signal to account
for the metabolite-specific variable flip angles used with the HFA sequence. This
adjustment means that the AUC ratio is still proportional to the rate constants of
conversion for the metabolites.
The AUC ratios for each metabolite were calculated by dividing the AUC for each
metabolite by the pyruvate AUC. The AUC ratio for each metabolite was assumed to be
directly proportional to its respective rate constant of conversion from pyruvate to
metabolite [62]. The AUC ratios for each metabolite were then compared between CDand WD-exposed placentae using nested ANOVA analysis with Satterthwaite’s method,
with α=0.05.

2.2.4.2.1

Litter Size, Pregnancy Loss/Success Rate, Incidence
of Abnormality Analysis

The litter size for each sow was determined using T1-w images from the time of MRI.
Any discernible placenta, regardless of its physical characteristics, was included in the
analysis. The mean litter size for both diet groups was then calculated by dividing the
sum of the individual litter sizes by the total number of litters in the respective diet group.
The litter size for each sow at collection was determined based on collections data and
included only sows that maintained pregnancy until the time of euthanasia and collection.
Pups deemed to be live, demised, or resorbing at collection were included in the litter
size. The mean litter size was calculated using the same procedure as for the mean litter
size at MRI.
The pregnancy loss rate was determined using a combination of post-MRI collections
data and pre-collections data. The sum of fetoplacental units deemed to be demised or
resorbing at the time of collection, in addition to pregnancies lost post-MRI but precollection (determined using litter size at MRI), was taken. This sum was then divided
by the total number of placentae from each diet group and multiplied by 100. The
pregnancy success rate was determined using collections data. Pups deemed to be “live”
at the time of collection were included in this calculation. The sum of “live” pups at
collection was divided by the total number of placentae from each diet group and
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multiplied by 100. The incidence of abnormal placentae was calculated using the
placental scores. Any placenta with a score higher than zero was considered abnormal.
The sum of abnormal placentae was taken and divided by the total number of placentae in
the respective diet group and multiplied by 100.

2.2.4.3

Statistical Analysis

Nested ANOVA and Welch’s t-test statistical analyses of the data were generated using R
(version 4.0.0)[70] for the placental score, diet, metabolic, volume and litter size data.
The nesting method selected (Satterthwaite’s method [76]) for the ANOVA accounted for
the semi-dependent nature of the placentae within the same litter while avoiding inflating
the n value artificially. Graphical representations of the data were generated using
GraphPad Prism version 8.0.0 for Mac OS X, (GraphPad Software, San Diego,
California, USA, www.graphpad.com) with α=0.05. The litter size was analyzed using a
simple mean calculation, as well as Welch’s t-test. The loss rate and incidence of
abnormality were analyzed using a simple percentage calculation.

Results

2.3

This section describes the results of the data anaylysis for the metabolic ratios, placental
score, placental volume, litter size, pregnancy loss rate, and the incidence of placental
abnormality.

2.3.1

Metabolite Production

APR and BPR (but not LPR) were found to vary significantly as a function of placental
score. The APR and BPR increased significantly with increases in placental score. No
significant variation was found in the LPR, APR, or BPR as a function of diet or
placental volume. The p-values obtained from the nested ANOVA statistical analyses are
summarised in Table 6. The LPR, APR, and BPR were calculated for every placenta
included in the metabolic data. The WD group contained 33 placentae, and the CD group
contained 13 placentae. The mean and standard deviation for the placental LPR, APR,
and BPR are summarizd in Table 7. The distribution of the data for the LPR, APR, and
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BPR within the diet groups is represented in Figure 6. The distribution of the data for the
LPR, APR, and BPR across placental score is represented in Figure 7.
Table 6: Summary of p-values for nested ANOVA statistical analyses. The titled
columns represent contributing factors. The titled rows represent factors analyzed
as dependent variables. * represents a statistically significant p-value
Diet

Placental Score

Placental Volume

APR

0.19

0.031*

0.21

BPR

0.19

0.0061*

0.22

LPR

0.41

0.10

0.37

Placental Score

0.08

Placental Volume

0.26

0.20
0.076

Table 7: Summary of the mean and standard deviation for the placental LPR, APR,
and BPR.
Metabolic Ratio

LPR

APR

BPR

Western Diet

0.14+/-0.059

0.10+/-0.050

0.12+/-0.048

Control Diet

0.11+/-0.048

0.066+/-0.037

0.083+/-0.023

Mean+/-SD
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A

B

0.4

0.3

APR

LPR

0.3
0.2
0.1
0.0

0.4

0.2
0.1

Control

Western

0.0

Control

Diet

Western

Diet

C 0.4
BPR

0.3
0.2
0.1
0.0

Control

Western

Diet

Figure 6: A-C. This figure demonstrates the distribution of the LPR (A), APR (B),
and BPR (C) data in CD- and WD-exposed placentae. No statistically significant
relationships were detected using a Nested ANOVA. Data points coded with the
same colour within a diet group are part of the same litter.
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A

B

0.4

0.3

APR

LPR

0.3
0.2
0.1

0.2
0.1

0.0

0.0
0

C

0.4

1

2

3

Placental Score

0.4

0

1

2

3

Placental Score

BPR

0.3
0.2
0.1
0.0
0

1

2

3

Placental Score
Figure 7: A-C. This figure represents the distribution of LPR (A), APR (B), and
BPR (C) data across placental score. Data points coded with the same colour are
part of the same litter. Statistically significant variation was detected for the APR
(B) and BPR (C), but not for the LPR (A) using a Nested ANOVA.

2.3.2

Placental Score

The placental score did not vary significantly as a function of diet or placental volume.
The mean placental score (p= 0.080 for diet, p=0.20 for placental volume) in the WD
group was 0.91+/-0.88 (33 placentae total) and 0.23+/-0.44 (13 placentae total) in the CD
group. The distribution of the placental score data within the diet groups is represented in
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Figure 8. Examples of normal and abnormal placental characteristics are demonstrated in
Figure 9. Motion artefact is demonstrated in Figure 10.

Placental Score

4
3
2
1
0
Control Western

Diet
Figure 8: This figure demonstrates the distribution of the placental score data
between CD- and WD-exposed placentae. No statistically significant relationships
were detected using a Nested ANOVA. Data points coded with the same colour
within a diet group are part of the same litter.
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Figure 9: A-F. T1-weighted images. A: demonstrates normal placentae. The white
arrows indicate normal-appearing placentae. B: demonstrates characteristics i and
ii from Table 5. The white arrow indicates a poorly visualized placenta. The black
arrow indicates a poorly differentiated placental border. C: demonstrates
characteristic iii from Table 5. The white arrow indicates the location of the
placenta. The black arrows indicate an irregular placental border. D: demonstrates
characteristic iv from Table 5. The white arrow indicates the location of the
placenta. The black arrow indicates an area of heterogeneity with increased signal
intensity relative to the rest of the placenta. E: demonstrates characteristic v from
Table 5. The black arrow indicates the location of the placenta. The white area
indicates a hyperintense placental border or "halo." F: demonstrates characteristic
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vi from Table 5. The white arrow indicates the location of the placenta, and the
black arrow indicates a hyperintense placental border. No discernible, associated
fetus could be identified in this instance.

Figure 10: T1-w image displaying motion artefact over the maternal abdominopelvic
region. The white arrows indicate motion artefact both external to the sow and
within the maternal abdominopelvic structures.

2.3.3

Placental Volume

The placental volume did not demonstrate significant variation as a function of diet or
placental score. The mean placental volume (p= 0.26 for diet, p=0.076 for placental
score) in the WD group was 1.6cc+/-0.82 (33 placentae total) and 1.3cc+/-0.22 (13
placentae total) in the CD group. Placental volume data distribution within the diet
groups is represented in Figure 11.
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Volume (cc)

4
3
2
1
0
Control Western

Diet
Figure 11: This figure demonstrates the distribution of the placental volume data
between CD- and WD-exposed placentae. No statistically significant relationships
were detected using a Nested ANOVA. Data points coded with the same colour
within a diet group are part of the same litter.

2.3.4

Litter Size

A Welch’s t-test in R (version 4.0.0) was used to analyze the litter size data. The litter
size data at MRI and collection is represented in Table 8 and Table 9, respectively. No
statistically significant differences in litter size at MRI or collection were detected
between diets (p=0.83 at MRI, p=0.97 at collection). No statistically significant
difference was found between the litter size at MRI and the litter size at collection in the
WD group (p=0.34). There was no difference between litter size at MRI and litter size at
collection in the CD group.
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Table 8: Summary of the mean litter size data at the time of MRI.
MRI

Mean Litter Size

Standard Deviation Total Litters

(pups/litter)
Western Diet (11

3.1

+/-0.88

11

3.3

+/-1.3

4

litters)
Control Diet (4
litters)

Table 9: Summary of mean litter size data at the time of tissue collection.
COLLECTION

Mean Litter Size

Standard Deviation Total Litters

(pups/litter)
Western Diet (6

3.5

+/-0.84

6

3.3

+/-1.3

4

litters)
Control Diet (4
litters)

2.3.5

Pregnancy Loss Rate

In the WD group (31 placentae total), 74% of pups were demised or resorbed at the time
of, or before collection, leaving 26% deemed to be live. The loss rate in the WD group is
2.4-fold higher than in the CD group. In the CD group (13 placentae total), 31% of pups
were demised or resorbing before or at the time of collection, leaving 69% deemed to be
live. The loss rate data is represented in Table 10.
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Table 10: Summary of loss rate data.
LOSS RATE

Demised/Resorbed

Live Fetoplacental

Total Placentae

Units
Fetoplacental Units
Western Diet

74%

26%

31

Control Diet

31%

69%

13

2.3.6

Incidence of Abnormality

77% of CD-exposed placentae (13 placentae total) were deemed to be “normal,” and 23%
were considered “abnormal.” In the WD group (33 placentae total), 36% of the placentae
were considered “normal,” and 64% of the placentae were deemed to be “abnormal.” A
64% incidence of abnormality represents a 2.8-fold increase in the incidence of
abnormality when compared to the CD group. The incidence of abnormality data is
represented in Table 11.
Table 11: Summary of the incidence of placental abnormality data.
INCIDENCE OF

Normal Placentae

ABNORMALITY

Abnormal

Total Placentae

Placentae

Western Diet

36%

64%

33

Control Diet

77%

23%

13
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2.4
2.4.1

Discussion
Metabolite Production

No statistically significant variations in metabolism were detected between the CD- and
WD-fed groups. The inability to detect such variations was potentially because data
from only one gestational age was examined. Data from later gestational ages may
demonstrate more pronounced variations as fetoplacental needs vary across gestation.
The use of data from a single gestational age was a limiting factor in this study, and data
from later gestational ages should be analyzed in the future. Secondly, the small sample
size, particularly in the CD group, likely impacted the statistical results of the study
leading to a type II error. When this study was conceived, it was not clear that nested
statistical analyses were necessary. Studies requiring nested statistical analyses typically
require larger sample sizes. As such, the results of this study were not sufficiently
powered to detect statistically significant variations.
Overall, metabolic, placental score, and volume data from WD-exposed placentae
demonstrated large variability when compared to CD-exposed placentae. Despite the
sows having been fed a lifelong WD, this variability may suggest that any potential
effects and/or the severity of effects from WD consumption are variable between sows
and between placentae from the same litter. The in-litter variability of the data implies
that individual fetoplacental units may respond and adapt differently in a challenging in
utero metabolic environment. The difference in response and adaptability between
fetoplacental units from the same litter may be due to the semi-independent nature of
fetoplacental units and genetic variation in a multiple-gestation environment.
Fetoplacental units from the same litter may experience differences in their in utero
environment. Most relevant to this study, variations in placental function, mainly
diffusion, osmosis, and endocrine function, are reported in human studies on multiple
gestation pregnancies where each fetus has a separate placenta [77]. Another possible
source of in-litter variation may be related to sex differences between the pups. Animal
studies using other rodent models have shown that male pups are more susceptible to
challenging in utero environments, including maternal diet-related factors, such as high
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fat and sugar diets. It is speculated that this increased susceptibility is due to variations in
placental structure and function of male pups [78].

2.4.2

Placental Characteristics and Score

The placenta is a temporary organ that ages over gestation and functionally declines by
the end of the gestational period. However, the placenta can age and decline in function
prematurely due to exposure to some pathological processes and environmental factors,
including preeclampsia, tobacco smoking, and diabetes [1]. Premature placental aging
and decline can lead to deleterious outcomes of pregnancy and might alter placental
function, including metabolism. The abnormal physical characteristics observed in the
placentae are potentially the result of premature placental aging and decline. The T1-w
MR characteristics of the placentae were suggestive of placental aging [1]. Some
characteristics of placental aging were consistent with a pathologist’s findings in 40-day
and 64-day GA WD-exposed placentae from a separate but similar study from a
collaborator’s laboratory. The pathologist (P.K) suggested that the histological findings
might be suggestive of premature placental aging. Given the 2.8-fold increase in the
incidence of abnormality in the WD-exposed placentae, the accelerated aging process of
the placentae may be due, at least in part, to oxidative stress and formation of reactive
oxygen species (ROS) induced by consumption of a WD (high fat and sugar). This
metabolically toxic environment may damage the placental mitochondria and lead to
mitochondrial dysfunction. Faced with chronic oxidative stress and ROS, placental tissue
may enter cellular senescence. Cellular senescence is a process that prevents further
cellular proliferation and regeneration and is a hallmark of cellular aging [79, 80].
The results presented in this study demonstrated statistically significant increases in the
APR and BPR when a placenta was identified as having abnormal characteristics. In
general, the trend revealed that as placental score increases, so does the APR and BPR.
The increase in APR in abnormal placentae provides evidence to suggest an increase in
placental ALT activity in those placentae [81]. When pyruvate and glutamate combine to
form α-ketoglutarate and alanine as a by-product, ALT is used as the catalyzing enzyme
[82]. The significance of the increased placental APR in the context of abnormal
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placental characteristics remains unclear. However, increases in placental APR may be
useful as a biomarker of fetoplacental metabolic health.
Though pyruvate is involved in energy production, in some instances of oxidative stress
with ROS production, it functions as an antioxidant to neutralize ROS. As an
antioxidant, pyruvate interacts with hydrogen peroxide to neutralize the ROS producing
CO2 and water as by-products. Though cells attempt to neutralize ROS using pyruvate,
this process is often ineffective as the stimulus for oxidative stress, and ROS formation
persists and overwhelms the cells [79]. The production of CO2 (in equilibrium with
bicarbonate) from the attempted ROS neutralization is potentially the source of the
increased BPR. As such, increases in placental BPR may also be useful as a biomarker
for fetoplacental health.
Placental scores were assigned to each placenta to indicate the presence or absence of
observable physical characteristics deemed to be abnormal. A diverse range of
characteristics considered abnormal was observed in the placentae of both CD- and WDexposed placentae. While both diet groups contained placentae identified as being
abnormal, a higher percentage (64%) of WD-exposed placentae were identified as being
abnormal compared to (23%) of CD-exposed placentae. It should also be noted that WDexposed placentae tended to possess more abnormal characteristics when compared to the
CD-exposed placentae, leading to higher placental scores (>1) in the WD group. Several
WD-exposed placentae were given placental scores of 2 or 3. The maximum score given
in the CD group was 1. From this data, it seemed that maternal consumption of a WD
had some association with the physical characteristics of the placentae though the nature
of that association remains unclear.
Overall poor visibility and differentiation of the placenta from surrounding tissues, as
well as poor differentiation between the placental border (plates) and parenchyma, may
be the result of poor or declining placental function. Tissue differentiation in imaging
studies is sometimes decreased or lost in the presence of chronic, progressive, or
inflammatory disease. For example, chronic renal disease with functional loss can lead to
poor corticomedullary differentiation on MRI as a result of a change in the tissue’s T1
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value in a disease state [83]. Another possible cause for reduced visibility and
differentiation and another limitation of this study was the motion artefact from the
peristalsis of maternal bowel overlying the fetoplacental units. Active bowel has the
potential to obscure or limit visualization of underlying and surrounding tissues.
However, the rater (M-E.E) was careful to identify the presence of motion artefact and
account for it when assessing the physical characteristics of the placentae.
An irregular, lobulated placental border is characteristic of an aging, declining placenta in
humans. While placental aging and decline is a normal process, environmental insults,
such as diabetes, can prematurely accelerate the process. Another characteristic common
to the placental aging process and other pathological processes, such as hypertension and
diabetes, is the development of placental infarcts. Infarcts are areas of tissue that have
lost their blood supply. These infarcted areas may calcify or become necrotic [1]. On
MRI, infarcts may appear as localized areas of hyperintensity. The presence of infarcted
placental parenchyma may explain the observation of heterogeneous placental
parenchyma.
The observed difference in signal intensity between the placental parenchyma and
placental border, where the placental border formed a hyperintense “halo” surrounding
the parenchyma, was potentially the result of a calcified placental border. Again,
calcification of the basal and chorionic plates (placental borders) in human beings is part
of the placental aging process but is concerning when it occurs before the later stages of
gestation. Early calcification in the placentae is more likely the result of a pathological
process rather than the normal, expected placental decline [1]. An alternate explanation
for the hyperintense “halo” observed in some placentae is proteinaceous edema of the
placental borders, perhaps due to an inflammatory process. Pathology reports from a
collaborator’s laboratory indicated the presence of edema in the chorionic plate of a 64day GA WD-exposed placenta. Though the pathologist (P.K) indicated that
inflammation was not apparent, there was evidence of cellular debris from macrophages,
which might suggest an inflammatory process.
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In one case, a complete fetoplacental unit could not be confidently identified. However,
the placenta was identified and segmented for volume, metabolic, and placental score
data. This placenta appeared grossly abnormal. It is possible that the associated fetus
was demised and had already been resorbed by the sow [84], making the identification of
a complete fetoplacental unit impossible. However, it is also possible that the complex
appearance of a grossly abnormal placenta in combination with often distended, gassy,
complex, active maternal bowel obscured any potentially viable fetal tissues beyond
recognition.

2.4.3

Placental Volume

As can be seen in Figure 11, there was considerable variation in the WD placental
volume data when compared to the CD data. This variability may be attributable to
variation in the effects of a WD on individual placentae within and between litters.

2.4.4

Litter Size

The total number of litters in the WD group varied between the mean litter size at MRI
and the mean litter size at collection calculation because some sows had demonstrably
lost their pregnancies before collection. The mean litter size at collection for the WD
group was increased compared to the mean litter size at MRI because some fetoplacental
units that were identified at the time of collection were not visualized on MRI. The
inability to visualize some fetoplacental units on MRI may have been due to the complex
appearance of the fetoplacental unit itself. It is also possible that the presence of complex,
gassy maternal bowel obscured or limited the identification of a fetoplacental unit.
Overall, the mean litter size between CD- and WD-fed sows was approximately equal,
suggesting that diet did not affect litter size at 33-days gestation.

2.4.5

Pregnancy Loss Rate

For the loss rate calculation, 31 placentae were included instead of 33 placentae as in the
metabolic data. Of the 33 placentae, one sow with three placentae was excluded from the
loss rate calculation because the sow was found deceased post-MRI, and therefore the
placentae were not included in the loss rate. One other placenta was added to the loss
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rate calculation because it was not visualized on MRI but was identified upon collection.
The 2.4-fold increase in fetoplacental loss in the WD-fed sows when compared to the
CD-fed sows suggested that WD consumption might have been a factor in the successful
maintenance of pregnancy. It could be speculated that the increase in loss rate was
associated with the 2.8-fold increase in the incidence of placental abnormality in the WDfed sows.

2.4.6

Incidence of Abnormality

The increased incidence of placental abnormality in the WD-fed sows suggested that WD
consumption has some relationship with the physical characteristics observed on MRI
and may contribute to premature placental aging. Consumption of a WD may also have
more variable effects in a biological system that are dependent on other factors present in
that system, accounting for the in-litter variability.

2.5

Conclusions

Lifelong consumption of a WD in pregnant GPs did not significantly affect placental
metabolism, score, or volume. However, a significant relationship between the placental
score and the APR and BPR was revealed. This relationship suggests that observing an
increase in placental APR and BPR may be useful as a biomarker of fetoplacental health.
The increased pregnancy loss rate in the WD-fed sows suggests that consumption of a
WD is somehow associated with increased rates of pregnancy loss. The increased
incidence of abnormality in the placentae of WD-fed sows suggests that WD
consumption may contribute to premature placental aging and have more insidious
placental effects than previously postulated. From this study, it is clear that additional
data is needed to elucidate the relationship between lifelong WD consumption and
fetoplacental health.
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Chapter 3

3

Future Work and Summary

This section details future work that would help to clarify the relationship between
lifelong WD consumption and fetoplacental health, such as the assessment of later
gestational ages, the TCA cycle, and analysis of other fetal organs and tissues that may
provide valuable information. A summary of the contents of this thesis is also provided.

3.1 Future Work
In Chapter 2, the glycolytic cycle was probed to quantify, indirectly, the conversion of [113

C] pyruvate to lactate, alanine, and bicarbonate. The [1-13C] label was useful for this

purpose. However, it was a limiting factor in that it was unable to provide critical
metabolic information regarding the TCA cycle (a part of aerobic cellular respiration)
because, chemically, the [1-13C] label does not transfer, through metabolic processes to
the intermediate metabolites involved in the TCA cycle. In order to probe the TCA
cycle, a [2-13C] label for pyruvate would be required. The [2-13C] label on pyruvate does
metabolize to [5-13C] glutamate. In a reversible transamination process, glutamate
converts to α-ketoglutarate- an intermediate metabolite of the TCA cycle. In this way,
information about the integrity of the TCA cycle in a challenged metabolic state could
potentially be investigated. Future studies employing a hyperpolarized [2-13C] pyruvate
probe have the potential to broaden our understanding of placental metabolism,
particularly as an indicator of aerobic cellular respiratory processes [60].
As detailed in Chapter 2, the metabolic activity, volume, and appearance of the placenta
were examined. While this study provided valuable information regarding the metabolic
health of the placenta and some of its physical characteristics, it did not examine relevant
information from some other key metabolically-active organs and tissues. Namely, the
maternal and fetal livers and adipose tissue were not examined in this study.
Consumption of a WD likely perturbs metabolism in such a way that metabolic pathways
might be altered, stimulating ectopic lipid deposition in the fetal and maternal livers
rather than in subcutaneous fat depots. Further studies could potentially examine the
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integrity of the metabolic pathways within the maternal and fetal livers by quantifying the
conversion of [1-13C]- and [2-13C] pyruvate to its spectrally visible metabolites. While
this quantification is possible in the maternal liver, the presence of a metabolic signal in
the fetal liver must be confirmed in order for this type of study to be feasible. The
percentage of fat (or lipid) contained within the fetal and maternal subcutaneous, intraabdominal, and intra-organ depots, and the volume of these tissues, should also be
quantified. The volume of adipose tissue depots and liver volume can be obtained
through manual segmentation. The percentage of fat or lipid in these tissues can be
determined by quantifying the fat fraction derived from IDEAL (fat and water) MRI
images. Qualitatively, tissue and organ appearance should be documented. The
collection of this data would provide a more global assessment of maternal and fetal
metabolic health, as well as provide morphological information regarding these tissues
and organs.
Next, in this study, only one gestational age was considered (33-day, mid-gestation).
Future studies should investigate [1-13C]- and [2-13C] pyruvate metabolism in the
placenta and maternal and fetal livers (if possible); the volume and appearance of the
placenta; subcutaneous, intra-abdominal, and intra-organ fat depots; and the fat fraction
of these fat depots should be documented across gestation. Specifically, this information
should be collected for 44-day and 60-day gestational age groups. This information may
be useful in determining the progression of metabolic effects related to the consumption
of a WD, as well as for comparison of metabolic effects between gestational age groups.
Finally, a major limiting factor of this study was the small sample size, considering the
need to perform nested statistical analyses and the larger n required for such analyses to
be accurate. In the future, additional data should be collected and analyzed in order to
make confident conclusions about the relationship between diet and placental metabolism
and characteristics.

3.2

Summary

This thesis investigated the effects of lifelong Western diet consumption during
pregnancy on the placenta in a guinea pig model of pregnancy. The guinea pig is
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considered an excellent model of human pregnancy because of its broadly similar fetal
development and placental structure and function. The placenta is a critical and
temporary fetal organ that acts as the maternal-fetal interface to support fetal growth and
development. The placenta performs immunologic and endocrine functions, as well as
providing nutrients to the fetus and allowing for gas exchange and waste removal.
Consumption of a WD, which is high in saturated fats and refined sugars and also
nutritionally poor, is linked to alterations in fetoplacental metabolic programming, which
may alter fetoplacental metabolism as an adaptive mechanism for short- and long-term
survival. These metabolic alterations are linked to an increase in the lifetime risk that an
exposed fetus will develop conditions such as CVD, obesity, and type II DM. It is
postulated that consumption of a WD may lead to a lipotoxic in utero environment that
results in the formation of reactive oxygen species and ultimately, oxidative damage to
the placental mitochondria. This damage may necessitate the cellular use of alternate,
less efficient metabolic pathways to meet fetoplacental energy requirements. As such,
glycolytic pathways may be favoured over oxidative metabolism in a challenged in utero
environment. An increase in glycolytic metabolism would result in increased lactate and
alanine production and decreased production of markers for oxidative metabolism, such
as bicarbonate.
Determining the potential metabolic effects of WD consumption is critical to
understanding and preserving fetoplacental health. This relationship is currently poorly
understood, but MRI imaging techniques, such as hyperpolarized 13C MRI, may be able
to provide valuable insight into fetoplacental metabolic health. Hyperpolarized 13Clabelled pyruvate is a metabolic probe capable of evaluating the metabolic conversion of
pyruvate to lactate, alanine, and bicarbonate. AUC ratios to quantify metabolite
production can be derived from the MR images collected using the hyperpolarized 13Clabelled pyruvate probe. These AUC ratios (LPR, APR, and BPR) are directly
proportional to the metabolic rate constants of conversion from pyruvate to lactate (kPL),
alanine (kPA), and bicarbonate (kPB). In conjunction with anatomical T1-w MRI for
placental localization and characterization, hyperpolarized 13C MRI can indicate
fetoplacental health status.
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In Chapter 2, 33-day gestation (~mid term) pregnant sows underwent conventional proton
and 13C metabolic MRI to investigate the relationship between lifelong WD consumption
and placental metabolism. Full-volume segmentations of the placentae were performed,
and the placentae were characterized using anatomical T1-w MR images. Metabolite
AUC ratios, proportional to their respective rate constants of conversion, were quantified
from the metabolic hyperpolarized 13C-labelled pyruvate images. A placental score,
based on placental characterization, was assigned to each placenta. Mean litter sizes at
MRI and tissue collection, as well as fetoplacental loss rate and the incidence of placental
abnormality, were calculated. A statistically significant relationship was detected
between the placental score and the APR and BPR but not the LPR. The APR and BPR
may be useful as biomarkers of fetoplacental health. No statistically significant
relationships were detected between the diet consumed and metabolite production,
placental score, volume or litter size at MRI and collection. Considerable variability was
noted in the WD group data between sows and within litters. Mean litter size was similar
between diet groups; however, pregnancy loss rate and incidence of placental
abnormality were increased in WD-exposed pregnancies. This study was limited by
small sample size. An additional limitation was the use of data from only one gestational
age. Future work should focus on increasing the sample size, including 44-day and 60day gestational ages in the data analysis, including other maternal and fetal organs in the
data analysis, and broadening the investigative scope of the metabolic probes.
Understanding and preserving fetoplacental health is critical for our short- and long-term
health, as well as for future generations. It is clear that continued, focused research is
necessary to clearly define the relationship between diet and metabolism throughout
pregnancy.
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